Bill
Bill > HRes1125
US HRes1125
US HRes1125Expressing support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics, and vaccines for COVID-19.
summary
Introduced
09/18/2020
09/18/2020
In Committee
09/18/2020
09/18/2020
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
This resolution expresses the sense of the House of Representatives that federal agencies should take appropriate actions to (1) ensure meaningful engagement of communities of color in the conduct of COVID-19 (i.e., coronavirus disease 2019) research and participation in clinical trials, and (2) improve equitable access to safe and effective vaccines.
Committee Categories
Business and Industry
Sponsors (23)
Eliot Engel (D)*,
Nanette Barragán (D),
Ami Bera (D),
Joaquin Castro (D),
Judy Chu (D),
Gil Cisneros (D),
Steve Cohen (D),
Adriano Espaillat (D),
Jahana Hayes (D),
Sheila Jackson-Lee (D),
Eddie Johnson (D),
Barbara Lee (D),
Elaine Luria (D),
Jim McGovern (D),
Gregory Meeks (D),
Jerry Nadler (D),
Eleanor Holmes Norton (D),
Donald Payne (D),
David Price (D),
Michael San Nicolas (D),
Terri Sewell (D),
Albio Sires (D),
David Trone (D),
Last Action
Referred to the House Committee on Energy and Commerce. (on 09/18/2020)
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/116th-congress/house-resolution/1125/all-info |
| BillText | https://www.congress.gov/116/bills/hres1125/BILLS-116hres1125ih.pdf |
| Bill | https://www.congress.gov/116/bills/hres1125/BILLS-116hres1125ih.pdf.pdf |
Loading...